A phase I trial of vertical inhibition of IGF signalling using cixutumumab, an anti-IGF-1R antibody, and selumetinib, an MEK 1/2 inhibitor, in advanced solid tumours

Por Wilky, B A, Rudek, M A, Ahmed, S, Laheru, D A, Cosgrove, D, Donehower, R C, Nelkin, B, Ball, D, Doyle, L A, Chen, H, Ye, X, Bigley, G, Womack, C, Azad, N S
Publicado no Br J Cancer (2015)

A Dose Finding Study of Temsirolimus and Liposomal Doxorubicin for Patients with Recurrent and Refractory Bone and Soft Tissue Sarcoma

Por Thornton, K. A., Chen, A. R., Trucco, M. M., Shah, P., Wilky, B. A., Gul, N., Carrera-Haro, M. A., Ferreira, M. Fogle, Shafique, U., Powell, J. D., Meyer, C. F., Loeb, D. M.
Publicado em 2013